These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28697164)

  • 21. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.
    Flank J; Schechter T; Gibson P; Johnston DL; Orsey AD; Portwine C; Sung L; Dupuis LL
    Support Care Cancer; 2018 Feb; 26(2):549-555. PubMed ID: 28856448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
    Shrewsbury SB; Hocevar-Trnka J; Satterly KH; Craig KL; Lickliter JD; Hoekman J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.
    Khan SS; Mican LM
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):671-7. PubMed ID: 17201611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.
    Freeman DJ; DiPaula BA; Love RC
    Pharmacotherapy; 2009 Aug; 29(8):930-6. PubMed ID: 19637946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective naturalistic multicenter study on choice of parenteral medication in psychiatric emergency settings in Japan.
    Hatta K; Katayama S; Morikawa F; Imai A; Fujita K; Fujita A; Ishizuka T; Abe T; Sudo Y; Hashimoto K; Usui C; Nakamura H; Yamanouchi Y; Hirata T;
    Neuropsychopharmacol Rep; 2018 Sep; 38(3):117-123. PubMed ID: 30175524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular ziprasidone: an effective agent for sedation of the agitated ED patient.
    Fulton JA; Axelband J; Jacoby JL; Heller MB
    Am J Emerg Med; 2006 Mar; 24(2):254-5. PubMed ID: 16490666
    [No Abstract]   [Full Text] [Related]  

  • 28. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
    Meehan K; Zhang F; David S; Tohen M; Janicak P; Small J; Koch M; Rizk R; Walker D; Tran P; Breier A
    J Clin Psychopharmacol; 2001 Aug; 21(4):389-97. PubMed ID: 11476123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.
    Wilson MP; MacDonald K; Vilke GM; Feifel D
    J Emerg Med; 2012 Nov; 43(5):790-7. PubMed ID: 21601409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Intravenous Olanzapine Administration at a Tertiary Academic Medical Center.
    Hunt NF; McLaughlin KC; Kovacevic MP; Lupi KE; Dube KM
    Ann Pharmacother; 2021 Sep; 55(9):1127-1133. PubMed ID: 33455436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of intravenous combination sedatives in the ED.
    Li SF; Kumar A; Thomas S; Sorokina Y; Calderon V; Dubey E; Lee L; Gustave L
    Am J Emerg Med; 2013 Sep; 31(9):1402-4. PubMed ID: 23928329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
    Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.
    Chinn E; Brunette ND; Driver BE; Klein LR; Stang JL; DeVries P; Mojica E; Raiter A; Miner JR; Cole JB
    Am J Emerg Med; 2023 Mar; 65():109-112. PubMed ID: 36603355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular Ziprasidone Dosing for Acute Agitation in the Pediatric Emergency Department: An Observational Study.
    Nguyen T; Stanton J; Foster R
    J Pharm Pract; 2018 Feb; 31(1):18-21. PubMed ID: 28205446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-dose intramuscular ketamine for severe agitation in an academic emergency department.
    O'Brien ME; Fuh L; Raja AS; White BA; Yun BJ; Hayes BD
    Clin Toxicol (Phila); 2020 Apr; 58(4):294-298. PubMed ID: 31335216
    [No Abstract]   [Full Text] [Related]  

  • 37. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
    Marder SR; Sorsaburu S; Dunayevich E; Karagianis JL; Dawe IC; Falk DM; Dellva MA; Carlson JL; Cavazzoni PA; Baker RW
    J Clin Psychiatry; 2010 Apr; 71(4):433-41. PubMed ID: 20156413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
    Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
    World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular olanzapine in the management of acute agitation.
    Tulloch KJ; Zed PJ
    Ann Pharmacother; 2004 Dec; 38(12):2128-35. PubMed ID: 15522977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.